NCT06010914View on ClinicalTrials.gov

A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2027

Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
OTHER

No Intervention

"Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information."

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY